Back

Long COVID is associated with extensive in-vivo neuroinflammation on DPA-714 PET

Visser, D.; Golla, S. S. V.; Verfaillie, S. C. J.; Coomans, E. M.; Rikken, R. M.; van de Giessen, E. M.; den Hollander, M. E.; Verveen, A.; Yaqub, M.; Barkhof, F.; Horn, J.; Koopman, B.; Schober, P.; Koch, D. W.; Schuit, R. C.; Windhorst, A. D.; Kassiou, M.; Boellaard, R.; van Vugt, M.; Knoop, H.; Tolboom, N.; van Berckel, B. N. M.

2022-06-04 infectious diseases
10.1101/2022.06.02.22275916 medRxiv
Show abstract

A significant number of COVID-19 patients develop long COVID, a condition defined by long-lasting debilitating, often neurological, symptoms. The pathophysiology of long COVID is unknown. Here we present in-vivo evidence of widespread neuroinflammation in long COVID, using a quantitative assessment, [18F]DPA-714 PET, in two long COVID patients. We reanalyzed historical data from three matched healthy control subjects, for comparison purposes. Both patients with long COVID had widespread increases in [18F]DPA-714 binding throughout the brain. Quantitative measures of binding (BPND values) were increased on average by 121% and 76%, respectively. This implicates profound neuroinflammation in the pathophysiology of long COVID.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.